AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript Summary
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript Summary
Full year 2024 revenue guidance raised to $459 million to $462 million, a growth projection of about 15% to 16% over 2023.The following is a summary of the AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript:
以下是atricure公司（ATRC）2024年第三季度業績會交易摘要：
Financial Performance:
金融業績：
AtriCure reported Q3 2024 total revenue of $116 million, reflecting an 18% growth.
Positive adjusted EBITDA of nearly $8 million for the quarter.
Full year 2024 revenue guidance raised to $459 million to $462 million, a growth projection of about 15% to 16% over 2023.
Positive cash flow of over $16 million generated this quarter.
AtriCure報告2024年第三季度總營業收入11600萬美元，增長18%。
本季度正調整後的息稅折舊及攤銷前利潤（EBITDA）接近800萬美元。
將2024年全年營業收入指導提高至45900萬至46200萬美元，相比2023年增長約15%至16%。
本季度現金流爲超過1600萬美元。
Business Progress:
業務進展：
Introduction of cryoSPHERE MAX and rapid adoption of cryoSPHERE+ in pain management, with a 36% growth worldwide.
Strong performance in the open ablation and appendage management franchises, particularly in the U.S.
Expansion in Europe with Encompass clamp and future growth anticipated in international markets with recent product launches and CE mark indications.
Progress in the LeAAPS clinical trial with nearly 3,700 patients enrolled, aiming for a total of 6,500 by mid-2025.
Entered into an exclusive license and development agreement to integrate PFA technology into cardiac surgery devices.
cryoSPHERE MAX的推出和cryoSPHERE+在疼痛管理中的迅速採用，全球增長36%。
在美國，開放消融和附件管理領域表現強勁。
通過Encompass夾具在歐洲的擴張，預計未來將在國際市場取得增長，最近的產品推出和CE標誌指引。
在LeAAPS臨床試驗中取得進展，目前已有近3,700名患者入組，計劃到2025年中旬達到6,500名患者。
簽署了獨家許可和開發協議，將PFA技術整合到心臟手術設備中。
Opportunities:
機會：
Market expansion with a focus on international growth, notably with the introduction of new products like the cryoSPHERE MAX and AtriClip FLEX Mini.
New product introductions and advances in product design, such as the cryoSPHERE MAX and AtriClip FLEX Mini, designed to enhance procedural efficiency and clinical outcomes.
Expanded CE mark indication for AtriClip devices and potential boost from the LeAAPS clinical trial to increase the addressable market size substantially.
在國際增長方面市場擴張，特別是通過引入新產品如cryoSPHERE MAX和AtriClip FLEX Mini。
通過新產品推出和產品設計的進展，如cryoSPHERE MAX和AtriClip FLEX Mini，旨在提高程序效率和臨床結果。
AtriClip設備擴大了CE標誌指引範圍，並有望通過LeAAPS臨床試驗獲得提升，大幅增加可觸達市場規模。
Risks:
風險：
Market effects of broadening PFA adoption pressuring pace of MIS adoption.
擴大PFA採用的市場影響正在加快MIS採用的步伐。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
